Michael D Wendt

Interaction with the S1 beta-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors.

V. Giranda, M. Wendt, V. Nienaber, 2004, Bioorganic & medicinal chemistry letters.

Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties.

Milan Bruncko, V. Giranda, D. Sauer, 2005, Bioorganic & medicinal chemistry letters.

Fragment-based discovery of potent inhibitors of the anti-apoptotic MCL-1 protein.

Chang Park, S. Swann, A. Petros, 2014, Bioorganic & medicinal chemistry letters.

Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection.

M. Wendt, Hui-ju Chen, Michael D Wendt, 2017, Journal of medicinal chemistry.

Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.

Saul H Rosenberg, Xiaohong Song, Milan Bruncko, 2008, Journal of medicinal chemistry.

Discovery of a novel small molecule binding site of human survivin.

Jun Chen, Saul H Rosenberg, Kenneth M Comess, 2007, Bioorganic & medicinal chemistry letters.

Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.

Mary K Joseph, Saul H Rosenberg, Xiaohong Song, 2007, Journal of medicinal chemistry.

Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution.

V. Giranda, M. Wendt, V. Nienaber, 2004, Journal of medicinal chemistry.